The ClinGen Evidence Repository is an FDA-recognized human genetic variant database containing expert-curated assertions regarding variants' pathogenicity and supporting evidence summaries. [Disclaimer]
  • Gene obtained from curated document aligns with the Allele Registry but not with ClinVar data
  • No CSPEC computed assertion could be determined for this classification!


Variant: NM_000261.2(MYOC):c.1091G>T (p.Gly364Val)

CA119170

7947 (ClinVar)

Gene: MYOC (HGNC:4653)
Condition: open-angle glaucoma (MONDO:0005338)
Inheritance Mode: Autosomal dominant inheritance
UUID: 30a3432f-835c-4e0b-942a-7a84d0c5f07c
Approved on: 2026-01-21
Published on: 2026-01-20

HGVS expressions

NM_000261.2:c.1091G>T
NM_000261.2(MYOC):c.1091G>T (p.Gly364Val)
NC_000001.11:g.171636349C>A
CM000663.2:g.171636349C>A
NC_000001.10:g.171605489C>A
CM000663.1:g.171605489C>A
NC_000001.9:g.169872112C>A
NG_008859.1:g.21285G>T
ENST00000037502.11:c.1091G>T
ENST00000637303.1:c.235-2281C>A
ENST00000638471.1:c.*429G>T
ENST00000037502.10:c.1091G>T
ENST00000614688.1:c.*55G>T
NM_000261.1:c.1091G>T
More

Pathogenic

Met criteria codes 5
PP3_Moderate PS3_Moderate PP1_Strong PS4_Supporting PM2_Supporting
Not Met criteria codes 9
BP7 BP4 PS2 PS1 BA1 PM5 PM4 BS3 BS1

Evidence Links 4

Expert Panel

Criteria Specification Information

Criteria Specification: ClinGen Glaucoma Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for MYOC Version 2.0.0

Criteria Specification Approval History
Criteria Specifications for this VCEP
Evidence submitted by expert panel
Glaucoma VCEP
The c.1091G>T variant in MYOC is a missense variant predicted to cause substitution of Glycine by Valine at amino acid 364 (p.Gly364Val). This variant was not found in any genetic ancestry group of gnomAD (v4.1.0), meeting the ≤ 0.0001 threshold set for PM2_Supporting in a genetic ancestry group of at least 10,000 alleles. The REVEL score = 0.896, which was within the 0.773-0.931 range for PP3_Moderate, predicting a damaging effect on MYOC function. The Gly364Val protein had increased instability and reduced secretion levels compared to wild type myocilin protein in these studies (PMIDs: 16466712, 21612213, 23129764). The assays met the OddsPath threshold for PS3_Moderate (> 4.3), indicating that this variant did impact protein function. This protein has also been assessed in these other studies (PMIDs: 10545602, 11152659, 15069026, 16297911), however, the same level of evidence was not met. 18 segregations in 2 families, with juvenile or primary open angle glaucoma (JOAG or POAG), have been reported (PMID: 9535666), which fulfilled PP1_Strong (≥7 meioses in >1 family). 2 probands with JOAG or POAG have been reported carrying this variant (PMID: 10196380), which met PS4_Supporting (≥ 2 probands). In summary, this variant met the criteria to receive a score of 10 and to be classified as pathogenic (pathogenic classification ≥ 10, adapted from PMID: 32720330) for juvenile open angle glaucoma based on the ACMG/AMP criteria met, as specified by the ClinGen Glaucoma VCEP (v2.0.0, 5 Dec 2024): PP1_Strong, PS3_Moderate, PP3_Moderate, PS4_Supporting, PM2_Supporting.
Met criteria codes
PP3_Moderate
The REVEL score = 0.896, which was within the 0.773-0.931 range for PP3_Moderate, predicting a damaging effect on MYOC function.
PS3_Moderate
The Gly364Val protein had increased instability and reduced secretion levels compared to wild type myocilin protein in these studies (PMIDs: 16466712, 21612213, 23129764). The assays met the OddsPath threshold for PS3_Moderate (> 4.3), indicating that this variant did impact protein function. This protein has also been assessed in these other studies (PMIDs: 10545602, 11152659, 15069026, 16297911), however, the same level of evidence was not met.

PP1_Strong
18 segregations in 2 families, with juvenile or primary open angle glaucoma (JOAG or POAG), have been reported (PMID: 9535666), which fulfilled PP1_Strong (≥7 meioses in >1 family).
PS4_Supporting
2 probands with JOAG or POAG have been reported carrying this variant (PMID: 10196380), which met PS4_Supporting (≥ 2 probands).
PM2_Supporting
This variant was not found in any genetic ancestry group of gnomAD (v4.1.0), meeting the ≤ 0.0001 threshold set for PM2_Supporting in a genetic ancestry group of at least 10,000 alleles.
Not Met criteria codes
BP7
This criterion did not apply to this variant.
BP4
This criterion was not met as PP3_Moderate has been met.
PS2
This variant has not been identified de novo.
PS1
An established LP or P variant causing this same amino acid change has not been identified.
BA1
This criterion was not met as PM2_Supporting has been met.
PM5
No other LP or P missense variants at this amino acid residue have been identified.
PM4
This criterion did not apply to this variant.
BS3
This criterion was not met as PS3_Moderate has been met.
BS1
This criterion was not met as PM2_Supporting has been met.
Curation History
The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.
ClinGen Terms of Use.
¤ Powered by BCM's Genboree.